148P Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Teiji Kuzuya, T. Yamashita, T. Takehara, Hiroshi Aikata, Naoya Kato, Yoichi Hiasa, Shinichiro Nakamura, N. Morimoto, M. Moriguchi, Masafumi Ikeda, Jun‐ichiro Inoue, Joji Tani, Yoshiyuki Ueno, Kazuaki Chayama, Ryosuke Tateishi, Y. Kawamura, Junji Furuse, Masatoshi Kudo, Kazuhiro Yamamoto, Norihiro Kokudo (2023). 148P Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR). , 34, DOI: https://doi.org/10.1016/j.annonc.2023.10.283.
